Tyra Biosciences, Inc. (TYRA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Tyra Biosciences reported revenue of $0. Net income was -$119.9M, or -$2.01 per diluted share. Operating activities generated -$95.1M of cash, leaving -$95.3M of free cash flow. At fiscal year end, Tyra Biosciences held $282.6M in total assets against $23.4M in total liabilities, including $77.4M of cash and equivalents.
Open the full interactive Tyra Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Tyra Biosciences Key Stats
| Share Price | $18.56 |
|---|---|
| Market Cap | $1.22B |
| 52-Week Range | $13.92 – $39.61 |
| Shares Outstanding | 66.0 million (basic, 2026 Q2) |
Tyra Biosciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$26.3M | -$58.9M | -$79.9M | -$104.2M | -$132.8M |
| Pre-Tax Income | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$119.9M |
| Income Tax | $1,000 | $2,000 | $0 | $0 | $0 |
| Net Income | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$119.9M |
| Diluted EPS | -$1.91 | -$1.32 | -$1.62 | -$1.51 | -$2.01 |
Tyra Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$29.9M | -$33.8M | -$39.3M | -$45.6M |
| Diluted EPS | -$0.50 | -$0.57 | -$0.64 | -$0.69 |
Tyra Biosciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $302.2M | $251.2M | $58.0M | $92.0M | $77.4M |
| Current Assets | $304.1M | $257.3M | $211.7M | $347.5M | $265.4M |
| Total Assets | $306.7M | $266.2M | $225.9M | $363.6M | $282.6M |
| Current Liabilities | $3.6M | $5.7M | $15.3M | $14.6M | $18.1M |
| Total Long-Term Debt | $200,000 | — | — | — | — |
| Total Liabilities | $5.0M | $8.4M | $21.6M | $20.4M | $23.4M |
| Shareholders' Equity | $301.7M | $257.8M | $204.3M | $343.2M | $259.2M |
Tyra Biosciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$23.7M | -$50.3M | -$50.1M | -$69.8M | -$95.1M |
| Cash From Investing | -$645,000 | -$559,000 | -$144.6M | -$98.4M | $72.5M |
| Cash From Financing | $311.3M | $632,000 | $1.5M | $202.1M | $8.1M |
| Free Cash Flow | -$24.4M | -$50.8M | -$50.9M | -$70.4M | -$95.3M |
Figures from Tyra Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tyra Biosciences financials page for every line item.
Tyra Biosciences Company Profile
| Ticker | TYRA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Carlsbad, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001863127 |
Frequently Asked Questions
What was Tyra Biosciences' revenue in fiscal 2025?
Tyra Biosciences (TYRA) reported revenue of $0 for fiscal 2025.
What is Tyra Biosciences' annual revenue history?
Tyra Biosciences' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Tyra Biosciences' net income in fiscal 2025?
Tyra Biosciences reported net income of -$119.9M for fiscal 2025.
What was Tyra Biosciences' earnings per share (EPS) in fiscal 2025?
Tyra Biosciences' diluted EPS was -$2.01 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tyra Biosciences generate in fiscal 2025?
Tyra Biosciences generated -$95.3M of free cash flow in fiscal 2025.
What was Tyra Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tyra Biosciences reported revenue of $0.
How many shares of Tyra Biosciences are outstanding?
Tyra Biosciences reported a weighted average of 66.0 million basic shares outstanding in 2026 Q2.
What is Tyra Biosciences' market cap?
Based on its latest closing price, Tyra Biosciences (TYRA) has a market capitalization of about $1.22B.
When does Tyra Biosciences' fiscal year end?
Tyra Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Tyra Biosciences headquartered?
Tyra Biosciences lists its business address in Carlsbad, California in its SEC filings.